264 related articles for article (PubMed ID: 15703820)
1. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
4. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.
Yang C; Klein EA; Assoian RK; Kazanietz MG
Biochem J; 2008 Feb; 410(1):167-75. PubMed ID: 17941827
[TBL] [Abstract][Full Text] [Related]
5. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
6. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
9. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
10. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
11. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
12. A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity.
Atlas E; Bojanowski K; Mehmi I; Lupu R
Oncogene; 2003 May; 22(22):3441-51. PubMed ID: 12776196
[TBL] [Abstract][Full Text] [Related]
13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation.
Wieder R; Fenig E; Wang H; Wang Q; Paglin S; Menzel T; Gabrilove J; Fuks Z; Yahalom J
J Cell Physiol; 1998 Dec; 177(3):411-25. PubMed ID: 9808150
[TBL] [Abstract][Full Text] [Related]
15. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells.
Vellon L; Menendez JA; Lupu R
Mol Carcinog; 2006 Oct; 45(10):795-804. PubMed ID: 16705745
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells.
Vadlamudi R; Adam L; Tseng B; Costa L; Kumar R
Cancer Res; 1999 Jun; 59(12):2843-6. PubMed ID: 10383144
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
18. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
Menendez JA; Colomer R; Lupu R
Med Hypotheses; 2005; 64(2):342-9. PubMed ID: 15607569
[TBL] [Abstract][Full Text] [Related]
19. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
[TBL] [Abstract][Full Text] [Related]
20. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
Ram TG; Kokeny KE; Dilts CA; Ethier SP
J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]